Estadísticas

 array:22 [
  "pii" => "S0001731014700146"
  "issn" => "00017310"
  "doi" => "10.1016/S0001-7310(14)70014-6"
  "estado" => "S300"
  "fechaPublicacion" => "2014-10-01"
  "aid" => "70014"
  "copyright" => "Academia Española de Dermatología y Venereología"
  "copyrightAnyo" => "2014"
  "documento" => "article"
  "subdocumento" => "fla"
  "cita" => "Actas Dermosifiliogr. 2014;105 Supl 1:9-20"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1123
    "formatos" => array:3 [
      "EPUB" => 36
      "HTML" => 327
      "PDF" => 760
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "S0001731014700158"
    "issn" => "00017310"
    "doi" => "10.1016/S0001-7310(14)70015-8"
    "estado" => "S300"
    "fechaPublicacion" => "2014-10-01"
    "aid" => "70015"
    "copyright" => "Academia Española de Dermatología y Venereología"
    "documento" => "article"
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2014;105 Supl 1:21-33"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 770
      "formatos" => array:3 [
        "EPUB" => 32
        "HTML" => 273
        "PDF" => 465
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease"
      "tienePdf" => "en"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "21"
          "paginaFinal" => "33"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "IL-17 e IL-17R: una diana terapéutica favorable para la enfermedad psoriásica"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A. Mitra, S.K. Raychaudhuri, S.P. Raychaudhuri"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "A."
              "apellidos" => "Mitra"
            ]
            1 => array:2 [
              "nombre" => "S.K."
              "apellidos" => "Raychaudhuri"
            ]
            2 => array:2 [
              "nombre" => "S.P."
              "apellidos" => "Raychaudhuri"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731014700158?idApp=UINPBA000044"
    "url" => "/00017310/00000105000000S1/v1_201411120051/S0001731014700158/v1_201411120051/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "S0001731014700134"
    "issn" => "00017310"
    "doi" => "10.1016/S0001-7310(14)70013-4"
    "estado" => "S300"
    "fechaPublicacion" => "2014-10-01"
    "aid" => "70013"
    "copyright" => "Academia Española de Dermatología y Venereología"
    "documento" => "simple-article"
    "subdocumento" => "edi"
    "cita" => "Actas Dermosifiliogr. 2014;105 Supl 1:6-8"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 460
      "formatos" => array:3 [
        "EPUB" => 28
        "HTML" => 245
        "PDF" => 187
      ]
    ]
    "en" => array:7 [
      "idiomaDefecto" => true
      "titulo" => "IL-17 in psoriasis. The final frontier or just another brick in the wall?"
      "tienePdf" => "en"
      "tieneTextoCompleto" => 0
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "6"
          "paginaFinal" => "8"
        ]
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J.M. Carrascosa, L. Puig"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "J.M."
              "apellidos" => "Carrascosa"
            ]
            1 => array:2 [
              "nombre" => "L."
              "apellidos" => "Puig"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731014700134?idApp=UINPBA000044"
    "url" => "/00017310/00000105000000S1/v1_201411120051/S0001731014700134/v1_201411120051/en/main.assets"
  ]
  "en" => array:11 [
    "idiomaDefecto" => true
    "titulo" => "Pathogenic role of IL-17 in psoriasis and psoriatic arthritis"
    "tieneTextoCompleto" => 0
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "9"
        "paginaFinal" => "20"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "A. Chiricozzi"
        "autores" => array:1 [
          0 => array:2 [
            "nombre" => "A."
            "apellidos" => "Chiricozzi"
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:2 [
            "entidad" => "Department of Dermatology, University of Rome Tor Vergata, Rome, Italy"
            "identificador" => "aff0005"
          ]
          1 => array:2 [
            "entidad" => "Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA"
            "identificador" => "aff0010"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Papel patógeno de la IL-17 en la psoriasis y en la artritis psoriásica"
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec360878"
          "palabras" => array:8 [
            0 => "IL-17"
            1 => "Psoriasis"
            2 => "Arthritis"
            3 => "Secukinumab"
            4 => "Ixekizumab"
            5 => "Brodalumab"
            6 => "Atherosclerosis"
            7 => "Obesity"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec360879"
          "palabras" => array:8 [
            0 => "IL-17"
            1 => "Psoriasis"
            2 => "Artritis"
            3 => "Secukinumab"
            4 => "Ixekizumab"
            5 => "Brodalumab"
            6 => "Aterosclerosis"
            7 => "Obesidad"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells&#46; Emerging evidence suggests a central role of IL-17 and IL-23&#47;T17 axis in the pathogenesis of psoriasis&#44; giving a rationale for using IL-17-blocking agents as therapeutics&#46;</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Three agents targeting IL-17 signaling are being studied in Phase III clinical trials&#58; secukinumab and ixekizumab &#40;IL-17 neutralizing agents&#41;&#44; and brodalumab &#40;IL-17 receptor antagonist&#41;&#46; Preliminary results are highly promising for all anti-IL17 agents&#44; creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis&#46;</p>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">La psoriasis es un trastorno cr&#243;nico inflamatorio de la piel resultante de un complejo sistema de citocinas y quimiocinas producidas por varios tipos de c&#233;lulas inmunes y c&#233;lulas tisulares&#46; La evidencia incipiente sugiere un papel central de la IL-17 y el eje IL-23&#47;T17 en la patog&#233;nesis de la psoriasis&#44; lo que ofrece una base para el uso de agentes bloqueadores de la IL-17 como tratamiento&#46;</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Est&#225;n siendo estudiados en estudios cl&#237;nicos en fase III tres agentes enfocados en la se&#241;alizaci&#243;n de la IL-17&#58; secukinumab e ixekizumab &#40;agentes neutralizantes de la IL-17&#41;&#44; y brodalumab &#40;antagonista del receptor de la IL-17&#41;&#46; Los resultados preliminares son altamente prometedores para todos los agentes anti-IL17&#44; lo que crea claras expectativas para esta clase de agentes como un nuevo planteamiento terap&#233;utico eficaz para el tratamiento de la psoriasis&#46;</p>"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/00017310/00000105000000S1/v1_201411120051/S0001731014700146/v1_201411120051/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6148"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Editorial"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/00000105000000S1/v1_201411120051/S0001731014700146/v1_201411120051/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731014700146?idApp=UINPBA000044"
]